HIV Clinic, Naval Medical Center San Diego, San Diego, California 92134-1005, USA.
AIDS Patient Care STDS. 2010 Jun;24(6):353-60. doi: 10.1089/apc.2009.0326.
Renal dysfunction is an increasingly recognized non-AIDS-defining comorbidity among HIV-infected persons. The role of HIV-related factors in renal dysfunction remains unclear. We performed a cross-sectional study at two military clinics with open access to care to determine the impact of HIV factors, including antiretroviral therapy, on renal function. Renal dysfunction was defined as a glomerular filtration rate (GFR) < 60 mL/min/1.73 m(2). We evaluated 717 HIV patients with a median age of 41 years; 92% were male, 49% Caucasian, and 38% African American; median CD4 count was 515 cells/mm(3) and 73% were receiving highly active antiretroviral therapy (HAART). Twenty-two patients (3%) had renal dysfunction. Factors associated with renal dysfunction in the multivariate logistic analyses included older age (odds ratio [OR] 2.0 per 10 year increase, p = 0.006), lower CD4 nadir (OR 0.6 per 100 cell change, p = 0.02), and duration of tenofovir use (OR 1.5 per year use, p = 0.01). Among persons initiating tenofovir (n = 241), 50% experienced a reduction in GFR (median -10.5 mL/min/1.73 m(2), 95% CI, -8.9 to -13.3) within 2 years. Among tenofovir users, factors associated with a reduction in GFR included female gender (p < 0.001), African American ethnicity (p = 0.003), and lower CD4 nadir (p = 0.002). In summary, renal dysfunction was relatively uncommon among our HIV-infected patients, perhaps due to their young age, lack of comorbidities, or as a result of our definition that did not include proteinuria. Renal dysfunction was associated with duration of tenofovir use. Factors associated with renal loss among tenofovir users included female gender, African American ethnicity, and CD4 nadir <200 cells/mm(3). Consideration for more frequent monitoring of kidney function among these select HIV patients may be warranted.
肾功能障碍是 HIV 感染者日益受到认可的非艾滋病定义性合并症。HIV 相关因素在肾功能障碍中的作用尚不清楚。我们在两家向公众开放的军事诊所进行了一项横断面研究,以确定 HIV 因素(包括抗逆转录病毒治疗)对肾功能的影响。肾功能障碍定义为肾小球滤过率(GFR)<60mL/min/1.73m²。我们评估了 717 名 HIV 患者,中位年龄为 41 岁;92%为男性,49%为白种人,38%为非裔美国人;中位 CD4 计数为 515 个细胞/mm³,73%正在接受高效抗逆转录病毒治疗(HAART)。22 名患者(3%)存在肾功能障碍。多变量逻辑分析中与肾功能障碍相关的因素包括年龄较大(每增加 10 岁,比值比[OR]增加 2.0,p=0.006)、CD4 最低点较低(OR 每 100 个细胞变化 0.6,p=0.02)和替诺福韦使用时间(OR 每年使用增加 1.5,p=0.01)。在开始使用替诺福韦的 241 人中,50%的患者在 2 年内 GFR 下降(中位数-10.5mL/min/1.73m²,95%CI,-8.9 至-13.3)。在替诺福韦使用者中,与 GFR 下降相关的因素包括女性(p<0.001)、非裔美国人(p=0.003)和 CD4 最低点较低(p=0.002)。总之,在我们的 HIV 感染者中,肾功能障碍相对少见,这可能是由于他们年轻、没有合并症,或者是由于我们的定义不包括蛋白尿。肾功能障碍与替诺福韦使用时间有关。替诺福韦使用者中与肾功能丧失相关的因素包括女性、非裔美国人以及 CD4 最低点<200 个细胞/mm³。考虑对这些特定的 HIV 患者更频繁地监测肾功能可能是必要的。